Claims
- 1. A topical cream pharmaceutical composition comprising:
- (a) 0.5 to 2.0 mg/g of at least one lipophilic steroid or antifungal drug;
- (b) 20 to 90 mg/g of diethyl sebacate or mineral oil;
- (c) 100 to 200 mg/g of white petrolatum;
- (d) 15 to 65 mg/g of propylene glycol stearate;
- (e) 30 to 75 mg/g of a mixture of stearyl alcohol and Ceteareth-20;
- (f) 5 to 20 mg/g of trimethylsiloxy-silicate;
- (g) 300 to 700 mg/g of purified water;
- (h) 20 to 120 mg/g of propylene glycol;
- (i) 5 to 15 mg/g of benzyl alcohol; and
- (j) 25 to 100 mg/g of N-methyl-2-pyrrolidone;
- and wherein the pH of said composition is adjusted to a value in the range of 4.5 to 6.5.
- 2. A topical lotion pharmaceutical composition comprising:
- (a) 0.5 to 2.0 mg/g of at least one lipophilic steroid or antifungal drug;
- (b) 20 to 90 mg/g of diethyl sebacate or mineral;
- (c) 50 to 100 mg/g of white petrolatum;
- (d) 15 to 65 mg/g of propylene glycol stearate;
- (e) 30 to 75 mg/g of a mixture of stearyl alcohol and Ceteareth-20;
- (f) 5 to 20 mg/g of trimethylsiloxy-silicate;
- (g) 400 to 800 mg/g of purified water;
- (h) 20 to 120 mg/g of propylene glycol;
- (i) 5 to 15 mg/g of benzyl alcohol; and
- (j) 25 to 100 mg/g of N-methyl-2-pyrrolidone;
- and wherein the pH of said composition is adjusted to a valve in the range of 4.5 to 6.5.
- 3. The pharmaceutical composition of claim 1 which contains 0.5 to 1.5 mg/g of a lipophilic steroid drug selected from mometasone furoate, betamethasone diproprionate, betamethasone valerate, alcolomethasone diproprionate, hydrocortisone and mixtures thereof.
- 4. The pharmaceutical composition of claim 1 which contains 5 to 15 mg/g of a lipophilic antifungal drug.
- 5. The pharmaceutical composition of claim 1 which contains 0.5 to 1.5 mg/g of a lipophilic steroid drug selected from mometasone furoate, betamethasone diproprionate, betamethasone valerate, alcomethasone diproprionate, hydrocortisone and mixtures thereof and 5 to 15 mg/g of a lipophilic antifungal drug.
- 6. The pharmaceutical composition of claim 2 which contains 0.5 to 1.5 mg/g of a lipophilic steroid drug selected from mometasone furoate, betamethasone diproprionate, betamethasone valerate, alcolomethasone diproprionte, hydrocortisone and mixtures thereof.
- 7. The pharmaceutical composition of claim 2 which contains 5 to 15 mg/g of a lipophilic antifungal drug.
- 8. The pharmaceutical composition of claim 2 which contains 0.5 to 1.5 mg/g of a lipophilic steroid drug selected from mometasone furoate, betamethasone diproprionate, betamethasone valerate, alcomethasone diproprionate, hydrocortisone and mixtures thereof and 5 to 15 mg/g of a lipophilic antifungal drug.
- 9. A topical cream pharmaceutical composition of claim 1, which comprises:
- a. 0.5 to 2.0 mg/g of at least one lipophilic steroid or antifungal drug;
- b. 35 mg/g of diethyl sebacate or mineral oil;
- c. 150 mg/g of white petrolatum;
- d. 40 mg/g of propylene glycol stearate;
- e. 55 mg/g of a mixture of stearyl alcohol and Ceteareth-20;
- f. 10 mg/g of trimethylsiloxy-silicate;
- g. 50 mg/g of propylene glycol;
- h. 10 mg/g of benzyl alcohol; and
- i. 50 mg/g of N-methyl-2-pyrrolidone;
- j. q.s. of purified water to 1 g; and wherein the pH of said composition is adjusted to a value in the range of 4.5 to 6.5.
- 10. A topical lotion pharmaceutical composition of claim 2 which comprises:
- a. 0.5 to 2.0 mg/g of at least one lipophilic steroid or antifungal drug;
- b. 35 mg/g of diethyl sebacate or mineral oil;
- c. 100 mg/g of white petrolatum;
- d. 25 mg/g of propylene glycol stearate;
- e. 25 mg/g of a mixture of stearyl alcohol and Ceteareth-20;
- f. 10 mg/g of trimethylsiloxy-silicate;
- g. 50 mg/g of propylene glycol;
- h. 10 mg/g of benzyl alcohol; and
- i. 50 mg/g of N-methyl-2-pyrrolidone
- j. q.s. mg/g of purified water to 1 g; and wherein the pH of said composition is adjusted to a valve in the range of 4.5 to 6.5.
Parent Case Info
The present application is the United States national application corresponding to International Application No. PCT/US90/07228, filed 14 Dec. 1990, and designating the United States, which PCT application is in turn a continuation of U.S. application Ser. No. 07/453,564, filed 20 Dec. 1989, now abandoned, the benefit of which applications is claimed pursuant to the provisions of 35 U.S.C. .sctn..sctn.120, 363 and 365(C).
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/US90/07228 |
12/14/1990 |
|
|
6/12/1992 |
6/12/1992 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO91/08733 |
6/27/1991 |
|
|
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
4039664 |
Stoughton et al. |
Aug 1977 |
|
4316893 |
Rajadhyaksha |
Feb 1982 |
|
4424234 |
Alderson et al. |
Jan 1984 |
|
4537776 |
Cooper |
Aug 1985 |
|
Foreign Referenced Citations (2)
Number |
Date |
Country |
0131228 |
Jan 1985 |
EPX |
0245126 |
Nov 1987 |
EPX |
Non-Patent Literature Citations (2)
Entry |
Chemical Abstracts (1977) vol. 87: 157098g (Vazquez et al.). |
Chemical Abstracts (1991) vol. 105: 30084j (Naito). |
Continuations (1)
|
Number |
Date |
Country |
Parent |
453564 |
Dec 1989 |
|